CV Therapeutics

How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions
How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions
Motley Fool
Gilead Sciences
M&A
CV Therapeutics
CGI Pharma
Arresto Biosciences
Calistoga Pharmaceuticals
Pharmasset
YM BioSciences
EpiTherapeutics
Flag link:
Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well
Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well
Endpoints
Gilead Sciences
addiction
GS-6637
CV Therapeutics
Flag link:
Leaner Isn't Meaner for 9 Big Pharma Firms That Tried to Cut Their Way to Greatness
Leaner Isn't Meaner for 9 Big Pharma Firms That Tried to Cut Their Way to Greatness
BNET Pharma
Pfizer
Merck
Wyeth
Schering Plough
GSK
Eli Lilly
Abbott Laboratories
Gilead Sciences
CV Therapeutics
consolidation
Flag link:
Big Pharma's Romance With Biotech Still Smolders, Despite Its Cold Shoulder to OSI
Big Pharma's Romance With Biotech Still Smolders, Despite Its Cold Shoulder to OSI
BNET Pharma
OSI Pharmaceuticals
Big Pharma
Astellas
Roche
Gilead Sciences
CV Therapeutics
Flag link:
One-Drug Wonders Deserve a Spot in Your Portfolio
One-Drug Wonders Deserve a Spot in Your Portfolio
Motley Fool
drug stocks
Omrix
JNJ
Gilead Sciences
CV Therapeutics
ImClone
Eli Lilly
Cougar Biotechnology
Flag link:
Gilead Preview: HIV Drugs Still Focus
Gilead Preview: HIV Drugs Still Focus
TheStreet.com
Gilead Sciences
HIV
CV Therapeutics
Flag link:
Gilead Sciences Completes Acquisition of CV Therapeutics
Gilead Sciences Completes Acquisition of CV Therapeutics
Yahoo
CV Therapeutics
Gilead Sciences
Flag link:
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
Seeking Alpha
biotech
Acorda Therapeutics
CV Therapeutics
Arena Pharmaceuticals
Genentech
Gilead Sciences
ZymoGenetics
ViroPharma
MAP Pharmaceuticals
Synta
La Jolla Pharmaceutical
Indevus
InterMune
Osiris Therapeutics
Flag link:
Gilead Sciences says regulators clear CV buyout
Gilead Sciences says regulators clear CV buyout
Yahoo/AP
Gilead Sciences
CV Therapeutics
buyouts
Flag link:
Credit Markets Aren't Stopping Health Care M&A
Credit Markets Aren't Stopping Health Care M&A
TheStreet.com
buyouts
Wyeth
Pfizer
Merck
Genentech
CV Therapeutics
Gilead Sciences
Schering Plough
Roche
Flag link:
Astellas Abandons Hostile Bid for CV Therapeutics
Astellas Abandons Hostile Bid for CV Therapeutics
Bloomberg
Astellas
CV Therapeutics
Gilead Sciences
buyouts
Flag link:
Big Mergers Could Mean Sweet Gains for Biotech
Big Mergers Could Mean Sweet Gains for Biotech
Seeking Alpha
biotech
Amgen
Gilead Sciences
CV Therapeutics
Biogen Idec
Genzyme
Biomarin
Medivation
Flag link:
Astellas May Abandon Chase for CV Therapeutics, Analysts Say
Astellas May Abandon Chase for CV Therapeutics, Analysts Say
Bloomberg
Astellas
buyouts
CV Therapeutics
Gilead Sciences
Flag link:
Gilead pulls CV Therapeutics from jaws of Astellas
Gilead pulls CV Therapeutics from jaws of Astellas
Yahoo/Reuters
Gilead Sciences
Astellas
CV Therapeutics
buyouts
Flag link:
Astellas Seeks to Oust CV Therapeutics Board in Takeover Bid
Astellas Seeks to Oust CV Therapeutics Board in Takeover Bid
Bloomberg
Astellas
CV Therapeutics
hostile takeover
buyouts
Flag link:
Astellas sues CV Therapeutics over rights plan
Astellas sues CV Therapeutics over rights plan
Yahoo
CV Therapeutics
Astellas
Flag link:
Astellas Files Lawsuit against CV Therapeutics
Astellas Files Lawsuit against CV Therapeutics
Yahoo
Astellas
CV Therapeutics
lawsuits
Flag link:
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash
Businesswire
CV Therapeutics
buyouts
Astellas
Flag link:
CV Therapeutics To Astellas: No Thanks
CV Therapeutics To Astellas: No Thanks
Forbes
CV Therapeutics
buyouts
Astellas
Flag link:
Astellas Pharma to continue pursuing buyout of CV Therapeutics following latest rejection
Astellas Pharma to continue pursuing buyout of CV Therapeutics following latest rejection
Yahoo/AP
Astellas
buyouts
CV Therapeutics
Flag link:

Pages